Concord Drugs Income Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Operating Revenue	512.41	452.45	449.25	520.81	589.57	513.57
Other Revenue	0	0	-	-	0.86	0.87
Revenue	512.41	452.45	449.25	520.81	590.43	514.44
Revenue Growth (YoY)	1.48%	0.71%	-13.74%	-11.79%	14.77%	0.03%
Cost of Revenue	418.51	356.47	337.33	415.96	425.7	434.11
Gross Profit	93.9	95.98	111.92	104.85	164.73	80.33
Selling, General & Admin	44.56	46.35	60.76	49.19	48.91	37.55
Other Operating Expenses	8.58	8.29	10.73	9.94	7.55	9.71
Operating Expenses	67.06	68.94	87.04	75.38	125.59	60.92
Operating Income	26.84	27.04	24.87	29.46	39.14	19.41
Interest Expense	-18.21	-19.19	-18.17	-16.34	-15.79	-13.31
Interest & Investment Income	0.14	0.14	0.09	0.06	0.12	0.08
Other Non Operating Income (Expenses)	-0.94	-1.08	-0.5	-0.7	-0.99	-0.89
EBT Excluding Unusual Items	7.84	6.91	6.29	12.49	22.48	5.29
Other Unusual Items	-	-	-	-	-	37.63
Pretax Income	7.84	6.91	6.29	12.49	22.48	42.92
Income Tax Expense	2.18	3.55	1.57	2.63	6.54	10.1
Net Income	5.66	3.36	4.72	9.86	15.94	32.82
Net Income to Common	5.66	3.36	4.72	9.86	15.94	32.82
Net Income Growth	-	-28.82%	-52.08%	-38.19%	-51.42%	899.60%
Shares Outstanding (Basic)	12	10	10	9	9	9
Shares Outstanding (Diluted)	12	10	10	9	9	9
Shares Change (YoY)	25.47%	-	7.35%	6.53%	-	-
EPS (Basic)	0.45	0.34	0.47	1.06	1.82	3.75
EPS (Diluted)	0.45	0.34	0.47	1.06	1.82	3.75
EPS Growth	-	-28.47%	-55.57%	-41.87%	-51.47%	898.78%
Free Cash Flow	-	13.89	-2.26	8.06	-16.82	-36.74
Free Cash Flow Per Share	-	1.39	-0.23	0.87	-1.92	-4.20
Gross Margin	18.32%	21.21%	24.91%	20.13%	27.90%	15.62%
Operating Margin	5.24%	5.98%	5.54%	5.66%	6.63%	3.77%
Profit Margin	1.10%	0.74%	1.05%	1.89%	2.70%	6.38%
Free Cash Flow Margin	-	3.07%	-0.50%	1.55%	-2.85%	-7.14%
EBITDA	40.21	41.34	40.43	45.72	56.79	33.06
EBITDA Margin	7.85%	9.14%	9.00%	8.78%	9.62%	6.43%
D&A For EBITDA	13.37	14.31	15.55	16.26	17.65	13.65
EBIT	26.84	27.04	24.87	29.46	39.14	19.41
EBIT Margin	5.24%	5.98%	5.54%	5.66%	6.63%	3.77%
Effective Tax Rate	27.79%	51.37%	24.89%	21.09%	29.08%	23.54%
Revenue as Reported	512.69	452.59	449.34	520.89	590.57	514.52

Source: S&P Global Market Intelligence. Standard template. Financial Sources.